CLN3 and Behcet disease: Together, we have developed a novel phenotypic screening tool for repurposing compounds able to reduce lysosomal Gb3 accumulation in BD cells and identified tamoxifen as a potential corrector of the most common subtypes of BD, CLN3 and CLN7 diseases.